A Phase II Trial of Daily Low-Dose Interleukin-2 (IL-2) for Steroid-Refractory Chronic Graft-Versus-Host-Disease.

Trial Profile

A Phase II Trial of Daily Low-Dose Interleukin-2 (IL-2) for Steroid-Refractory Chronic Graft-Versus-Host-Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs Interleukin-2 (Primary) ; Prednisone
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Apr 2016 Status changed from active, no longer recruiting to completed according to results published in the Blood.
    • 12 Apr 2016 Results published in the Blood
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top